Leucovorin Pharmacenter (Folinic Acid)

Folinic acid is a reduced folate that bypasses the block created by methotrexate on dihydrofolate reductase. By replenishing tetrahydrofolate pools, it restores normal DNA synthesis in healthy cells, protecting them from methotrexate damage, while also stabilising the metabolic pathway that allows 5‑fluorouracil to act more effectively on tumour cells.

The specific dose and schedule of Leucovorin Pharmacenter are determined by the prescribing clinician based on the indication, patient weight, renal function, and the chemotherapy regimen being used. Healthcare professionals should follow institutional protocols and product labeling when calculating the appropriate dose.

The safety of folinic acid in pregnancy has not been fully established, and it is classified as a pregnancy category with unknown risk. It should only be used if the potential benefit justifies the potential risk to the fetus. Breastfeeding mothers should consult their physician, as the drug may be excreted in breast milk.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and required import documentation.

Leucovorin (folinic acid) is the standard rescue agent for methotrexate toxicity because it directly restores folate metabolism without requiring activation. Alternatives such as calcium folinate are chemically similar, but folinic acid offers more predictable pharmacokinetics and is preferred in many oncology protocols for its rapid intracellular conversion.

Leucovorin Pharmacenter should be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken vigorously. Vials should remain in their original packaging until use to maintain sterility and potency.

Leucovorin is supplied as a sterile injectable solution and is administered either intravenously or intramuscularly by a qualified healthcare professional. The route, rate of infusion, and timing relative to chemotherapy are determined by the treating physician and institutional guidelines.

Serious risks, although rare, include anaphylactic reactions, severe hypotension during infusion, acute renal dysfunction, Stevens‑Johnson syndrome, and significant thrombocytopenia. Prompt recognition and immediate medical intervention are essential if any of these events occur.

Patients with known hypersensitivity to folinic acid or any component of the formulation should avoid Leucovorin. Additionally, individuals with severe renal impairment, uncontrolled electrolyte disturbances, or those receiving contraindicated antifolate therapies should not be given the drug without careful medical evaluation.